Tessera Therapeutics
Ilya Shestopalov, PhD, currently serves as Vice President of Analytical Development at Tessera Therapeutics, a position held since January 2025. Prior to this role, Ilya was with bluebird bio from September 2014 to January 2025, where Ilya progressed through various leadership positions in Analytical Development, including Vice President and Analytical Product Lead. Earlier experience includes serving as a Senior Scientist, managing a team and leading the development of a single cell PCR assay, and postdoctoral work at Children's Hospital Boston, where Ilya was a project leader in stem cell research. Educational credentials include a Ph.D. in Chemical Biology from Stanford University and a B.S. in Biological Chemistry from the University of Chicago.
This person is not in any teams
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.